Trial reportFrontiers in reproductive health2026
Efficacy and safety of nalbuphine vs. pethidine in oocyte retrieval: a non-inferiority, double-blinded, randomized controlled trial.
Trial report in Frontiers in reproductive health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The purpose of this study was to evaluate the efficacy and safety of Nalbuphine compared to Pethidine for pain relief during oocyte retrieval. Methods: In a double-blinded, non-inferiority randomized controlled trial ( Results: Nalbuphine demonstrated non-inferiority to Pethidine for pain control at 0 h postoperatively, with a mean difference of 0.52 (95% CI: -0.40 to 1.44). Similar findings were observed at 2 h (mean difference -0.46; 95% CI: -1.30 to 0.38), while at 6 h Nalbuphine showed significantly lower pain scores (mean difference -1.28; 95% CI: -2.15 to -0.41). No significant differences were observed between groups in operator score, recovery time, or rescue analgesia requirements. The number and quality of oocytes retrieved were not affected by the analgesic regimen. Side effects such as nausea, vomiting, dizziness, and tachycardia were compared and showed no significant differences. Conclusion: Nalbuphine demonstrated non-inferior analgesia to Pethidine for oocyte retrieval with a favorable safety profile. Its impact on long-term reproductive outcomes and clinical superiority warrants further investigation. Clinical Trial Registration: https://www.thaiclinicaltrials.org/show/TCTR20240406003, identifier TCTR20240406003.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.